Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCyclopharm Ltd

Cyclopharm Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.455 AUD -0.01 ( 2.15%)
Last update at 2026-11-06T05:10:00Z
VOLUME
29449
Market Cap
57.21M

Momentum Score

…

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.45
Low
0.46
High
52 Week Price Range
0.33
Low
1.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cyclopharm Ltd develops and supplies Technegas, a diagnostic system and single-use consumables for lung ventilation imaging in nuclear medicine.

Long-term growth may be driven by broader clinical adoption, higher prevalence of respiratory disease and recurring consumable sales from an expanding installed base, and investors may find it attractive for its consumable-led revenue model and focused niche in pulmonary diagnostics.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.47
Dividend Yield
-
Revenue TTM
34.42M
Revenue Per Share
0.30
Gross Profit TTM
19.46M
Debt / Equity
0.55
ROE
-53.92%
Net Debt
8.29M
ROCE
-52.19%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.86M -13.07M -4.19M -6.03M -4.35M
Net income -17.22M -13.20M -4.70M -6.61M -5.04M
Selling general administrative - 21.48M 14.00M 10.96M 10.30M
Selling and marketing expenses - 3.15M 2.05M 2.92M 1.02M
Gross profit -1.46M 17.93M 16.08M 15.78M 12.66M
Reconciled depreciation - 1.48M 0.94M 0.93M 0.76M
Ebit -18.18M -14.52M -4.77M -5.96M -4.33M
Ebitda -16.41M -13.69M -3.84M -5.03M -3.57M
Depreciation and amortization 1.77M 0.83M 0.94M 0.93M 0.76M
Operating income -18.18M -14.35M -5.26M -5.96M -4.33M
Other operating expenses 50.51M 41.92M 36.36M 30.85M 24.66M
Interest expense 0.63M 0.32M 0.22M 0.07M 0.02M
Tax provision - 0.13M 0.51M 0.58M 0.69M
Interest income - 0.67M 0.49M 0.11M 0.09M
Net interest income - 0.35M 0.27M -0.16M -0.09M
Income tax expense -0.64M 0.13M 0.51M 0.58M 0.69M
Total revenue 32.33M 27.57M 26.34M 23.22M 17.70M
Total operating expenses 16.72M 32.28M 13.72M 23.41M 19.61M
Cost of revenue 33.78M 9.64M 22.64M 7.44M 5.04M
Total other income expense net 0.33M 1.45M 5.84M -0.07M -0.02M
Net income from continuing ops - -13.20M -4.70M -6.61M -5.04M
Net income applicable to common shares - -13.20M -4.70M -6.61M -5.04M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 46.10M 62.13M 45.91M 49.54M 55.74M
Intangible assets 1.70M 4.18M - 4.57M 4.56M
Other current assets 1.81M 2.43M 0.45M 0.57M 0.39M
Total liab 18.99M 19.40M 13.65M 13.01M 12.67M
Total stockholder equity 27.11M 42.73M 32.26M 36.54M 43.07M
Deferred long term liab - - - 0.79M 0.79M
Other current liab 6.64M 6.19M 5.27M 3.33M 5.07M
Common stock 87.07M 92.41M 63.78M 63.42M 62.97M
Capital stock - - - 63.42M 62.97M
Retained earnings -65.08M -47.86M -34.66M -29.07M -21.58M
Other liab - - - 0.95M 0.92M
Good will 0.97M 0.93M 0.90M 0.87M 0.87M
Other assets - - 0.00M 0.64M 1.61M
Cash 6.63M 20.57M 11.73M 20.30M 29.25M
Total current liabilities 11.26M 10.61M 8.67M 7.94M 7.42M
Current deferred revenue - - 0.04M - -
Net debt 8.29M -12.28M -7.50M -15.96M -24.74M
Short term debt 0.56M 0.63M 0.21M 0.21M 0.18M
Short long term debt total 14.92M 8.29M 4.23M 4.33M 4.51M
Other stockholder equity - -0.00M - -1.05M -3.66M
Property plant equipment - - - 6.60M 6.25M
Total current assets 28.46M 42.39M 30.20M 36.87M 43.25M
Net tangible assets - - - 31.89M 38.43M
Short term investments - 1.23M - - -
Net receivables 8.59M 4.91M 7.90M 7.71M 8.04M
Inventory 11.43M 13.25M 10.12M 8.29M 5.51M
Accounts payable 4.06M 3.80M 3.15M 4.40M 2.17M
Accumulated other comprehensive income 5.11M -1.82M 3.14M 2.19M 1.67M
Non currrent assets other - 1.53M 0.03M - -
Non current assets total 17.64M 19.74M 15.72M 12.67M 12.49M
Capital lease obligations - - - 4.33M 4.51M
Long term debt total - - - 4.12M 4.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.97M -0.51M -1.55M -1.16M
Change to liabilities - - - 1.08M 1.82M
Total cashflows from investing activities 3.00M -0.97M -0.51M -1.55M -1.16M
Net borrowings - - - -0.29M -0.29M
Total cash from financing activities -1.12M 22.22M -1.02M -0.73M 30.17M
Change to operating activities - - - 0.74M 0.02M
Net income -17.22M -13.20M -4.70M -6.61M -5.04M
Change in cash -13.94M 8.84M -8.57M -8.95M 27.37M
Begin period cash flow 20.57M 11.73M 20.30M 29.25M 1.87M
End period cash flow 6.63M 20.57M 11.73M 20.30M 29.25M
Total cash from operating activities -17.33M -12.57M -7.20M -5.68M -1.63M
Issuance of capital stock - 24.00M - - 33.00M
Depreciation 1.77M 1.48M 0.94M 0.93M 0.76M
Other cashflows from investing activities - -0.17M -0.30M - 0.00M
Dividends paid - 0.00M -0.88M -0.88M -0.88M
Change to inventory -0.81M -3.09M -1.86M -2.78M -0.78M
Change to account receivables -1.69M 0.24M -0.49M -0.59M 0.69M
Sale purchase of stock - -1.14M - 0.00M -1.66M
Other cashflows from financing activities -1.12M 0.01M 0.14M 0.16M -0.29M
Change to netincome - - - 0.52M 0.75M
Capital expenditures 1.99M 0.97M 0.54M 1.55M 1.16M
Change in working capital -2.85M -2.61M -1.93M 0.45M 0.40M
Stock based compensation - 0.36M 0.52M - -
Other non cash items 0.97M 1.75M -0.98M 5.68M 4.28M
Free cash flow -19.32M -13.55M -7.74M -7.23M -2.79M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CYC
Cyclopharm Ltd		 -0.01
2.15%		 0.46 - 116.28 1.66 1.93 3.23 -24.57
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17 6.76 15.37

Profile*

Cyclopharm Ltd

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.

1 The Crescent, Kingsgrove, NSW, Australia, 2208

61 2 9541 0411

https://www.cyclomedica.com/company/cyclopharm/

104

Name Title Year Born
Mr. James S. McBrayer F.A.C.I.D., BSPharm, GDM, FAICD, AIM CEO, MD, Company Sec. & Director 1965
Mr. Mathew Farag Chief Operating Officer NA
Mr. Graham N. Phillips Fin. Mang. NA
Dr. Mark Doverty Global Head of Regulatory Compliance & Clinical Research NA
Ms. Sally-Ann Cornelius Head of Sales NA
Ms. Niamh McAree Head of Quality and Regulatory NA
Mr. Chris Quinn Head of Service NA
Ms. Sui Ling Cheah Financial Controller 1970
Mr. Lynn McLauchlin Gen. Mang. of Canada NA
Mr. Gary T. Somerville Quality & Regulatory Mang. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…